Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future

Evaluation of the efficacy and the safety of lanreotide autogel 120 mg on tumor growth stabilization in patients with progressive neuroendocrine tumors (NETs) who are not eligible to surgery or chemotherapy.

(2017) M. Martin-Richard et al.   JOURNAL OF CLINICAL ONCOLOGY

Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study

(2016) Jakob Dal et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Patchwork

(2016) Mary M.W. Billington   JOURNAL OF CLINICAL ONCOLOGY

Octreotide LAR: safety and tolerability issues

(2016) Jan Bornschein et al.   Expert Opinion On Drug Safety

Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers

(2015) Fredrik Tiberg et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo armpost hocanalysis

(2015) Jonathan R Strosberg et al.   ENDOCRINE-RELATED CANCER

Mortality in acromegaly: a 20-year follow-up study

(2015) Elina Ritvonen et al.   ENDOCRINE-RELATED CANCER

Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial

(2015) Shlomo Melmed et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Cardiovascular Disease and Sleep-Disordered Breathing in Acromegaly

(2015) Andrew S. Powlson et al.   NEUROENDOCRINOLOGY

Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study

(2015) Philippe J. Caron et al.   Pituitary

Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly

(2015) Annamaria Colao et al.   Pituitary

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

(2015) Edward Wolin et al.   Drug Design Development and Therapy

Drug delivery applications of non-lamellar liquid crystalline phases and nanoparticles

(2015) F. Tiberg et al.   JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY

Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial

(2014) S L Fougner et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Long-Term Efficacy and Safety of Pegvisomant in Combination With Long-Acting Somatostatin Analogs in Acromegaly

(2014) S. J. C. M. M. Neggers et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis

(2014) John D. Carmichael et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Acromegaly: An Endocrine Society Clinical Practice Guideline

(2014) Laurence Katznelson et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study

(2014) A. Colao et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy

(2014) E. Ghigo et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

(2014) Martyn E. Caplin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial

(2014) Mônica R Gadelha et al.   Lancet Diabetes & Endocrinology

Resistance to octreotide LAR in acromegalic patients with high SSTR2 expression: analysis of AIP expression

(2013) Leandro Kasuki et al.   Arquivos Brasileiros de Endocrinologia e Metabologia

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly-2011 Update

(2013) Laurence Katznelson et al.   Endocrine Practice

Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours

(2013) A. Romer et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial

(2013) Philippe J. Caron et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Targeted Therapies in Neuroendocrine Tumors (NET): Clinical Trial Challenges and Lessons Learned

(2013) J. C. Yao et al.   ONCOLOGIST

Biochemical and quality of life responses to octreotide-LAR in acromegaly

(2013) Ruth Mangupli et al.   Pituitary

Neurocognitive Function in Acromegaly after Surgical Resection of GH-Secreting Adenoma versus Naïve Acromegaly

(2013) Juan Francisco Martín-Rodríguez et al.   PLoS One

Place of Preoperative Treatment of Acromegaly with Somatostatin Analog on Surgical Outcome: A Systematic Review and Meta-Analysis

(2013) Francisco Pita-Gutierrez et al.   PLoS One

Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2012) K. Oberg et al.   ANNALS OF ONCOLOGY

Phase Behavior, Functions, and Medical Applications of Soy Phosphatidylcholine and Diglyceride Lipid Compositions

(2012) Fredrik Tiberg et al.   CHEMISTRY LETTERS

Tolerability and Dose Proportional Pharmacokinetics of Pasireotide Administered as a Single Dose or Two Divided Doses in Healthy Male Volunteers: A Single-Center, Open-Label, Ascending-Dose Study

(2012) Stephan Petersenn et al.   CLINICAL THERAPEUTICS

Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study

(2012) Larry K Kvols et al.   ENDOCRINE-RELATED CANCER

Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study

(2012) H. Dietrich et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Lutetium-labelled peptides for therapy of neuroendocrine tumours

(2012) B. L. R. Kam et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY

(2012) A. J. van der Lely et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Immunoreactivity Score Using an Anti-sst2A Receptor Monoclonal Antibody Strongly Predicts the Biochemical Response to Adjuvant Treatment with Somatostatin Analogs in Acromegaly

(2012) Federico Gatto et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers

(2012) Linda Villard et al.   JOURNAL OF CLINICAL ONCOLOGY

A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease

(2012) Annamaria Colao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antitumor Effects of Somatostatin Analogs in Neuroendocrine Tumors

(2012) L. Sideris et al.   ONCOLOGIST

Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly

(2012) Andrea Giustina et al.   PLoS One

Novel pathway for somatostatin analogs in patients with acromegaly

(2012) Mônica R. Gadelha et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Resistance to Somatostatin Analogs in Acromegaly

(2011) Annamaria Colao et al.   ENDOCRINE REVIEWS

Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy

(2011) Gherardo Mazziotti et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying?

(2011) Claudia Ramírez et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Place of Cabergoline in Acromegaly: A Meta-Analysis

(2011) Laure Sandret et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting

(2011) Matthew H. Kulke et al.   JOURNAL OF CLINICAL ONCOLOGY

Pasireotide (SOM230), a Novel Multireceptor-Targeted Somatostatin Analogue, Is Well Tolerated When Administered as a Continuous 7-Day Subcutaneous Infusion in Healthy Male Volunteers

(2011) Stephan Petersenn et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effects of somatostatin analogs on glucose homeostasis in rats

(2011) Herbert A Schmid et al.   JOURNAL OF ENDOCRINOLOGY

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

(2011) Marianne E Pavel et al.   LANCET

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical, quality of life, and economic value of acromegaly disease control

(2011) A. Ben-Shlomo et al.   Pituitary

Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy

(2010) Su-Jung Kim et al.   BMC CANCER

Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study

(2010) Ming Shen et al.   ENDOCRINE JOURNAL

Mortality in Patients with Pituitary Disease

(2010) Mark Sherlock et al.   ENDOCRINE REVIEWS

Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial

(2010) Zhi-gang Mao et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Endocrine Aspects of Obstructive Sleep Apnea

(2010) Pierre Attal et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Evidence of Cognitive and Neurophysiological Impairment in Patients with Untreated Naive Acromegaly

(2010) José Leon-Carrion et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Elucidation of the Self-Assembly Pathway of Lanreotide Octapeptide into β-Sheet Nanotubes: Role of Two Stable Intermediates

(2010) Emilie Pouget et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

The NANETS Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors (NETs)

(2010) Lowell B. Anthony et al.   PANCREAS

The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors

(2010) J. Philip Boudreaux et al.   PANCREAS

Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review

(2010) Maria Fleseriu   Pituitary

A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly

(2009) Peter J. Trainer et al.   CLINICAL ENDOCRINOLOGY

Prevalence of mental disorders in acromegaly: a cross-sectional study in 81 acromegalic patients

(2009) Caroline Sievers et al.   CLINICAL ENDOCRINOLOGY

High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial

(2009) Andrea Giustina et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Effects of Somatostatin Analogs on Glucose Homeostasis: A Metaanalysis of Acromegaly Studies

(2009) Gherardo Mazziotti et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

(2009) Anja Rinke et al.   JOURNAL OF CLINICAL ONCOLOGY

Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival

(2008) T. R. Halfdanarson et al.   ANNALS OF ONCOLOGY

Disease-specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas

(2008) Agatha A. van der Klaauw et al.   CLINICAL ENDOCRINOLOGY

A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly

(2008) I M Holdaway et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Quantitative analysis of somatostatin receptor subtypes (1–5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR

(2008) Giselle F Taboada et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance

(2008) Maria P Matta et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Personality in patients with pituitary adenomas is characterized by increased anxiety-related traits: comparison of 70 acromegalic patients with patients with non-functioning pituitary adenomas and age- and gender-matched controls

(2008) C Sievers et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly

(2008) Robert D. Murray et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Divergence between Growth Hormone and Insulin-Like Growth Factor-I Concentrations in the Follow-Up of Acromegaly

(2008) Orsalia Alexopoulou et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Preoperative Octreotide Treatment in Newly Diagnosed Acromegalic Patients with Macroadenomas Increases Cure Short-Term Postoperative Rates: A Prospective, Randomized Trial

(2008) Sven M. Carlsen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Selective Loss of Somatostatin Receptor 2 in Octreotide-Resistant Growth Hormone-Secreting Adenomas

(2008) Ursula Plöckinger et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Impact of Somatostatin AnalogsVersusSurgery on Glucose Metabolism in Acromegaly: Results of a 5-Year Observational, Open, Prospective Study

(2008) Annamaria Colao et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk of colorectal neoplasm in patients with acromegaly: A meta-analysis

(2008) Theodoros Rokkas et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Mortality in Acromegaly: A Metaanalysis

(2007) O. M. Dekkers et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pasireotide (SOM230): Development, mechanism of action and potential applications

(2007) Herbert A. Schmid   MOLECULAR AND CELLULAR ENDOCRINOLOGY